NCT05199584 2026-03-05A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function MutationsEndeavor Biomedicines, Inc.Phase 2 Completed20 enrolled
NCT04284774 2025-12-04Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialNational Cancer Institute (NCI)Phase 2 Active not recruiting5 enrolled 9 charts
NCT02034110 2023-08-21Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare CancersNovartisPhase 2 Completed206 enrolled 40 charts 2 FDA
NCT01966809 2019-08-20Photodynamic Therapy (PDT) For Recurrent High Grade GliomasMedical College of WisconsinPhase 2 Terminated1 enrolled 5 charts